MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

The Lancet

Volumn 391, Issue 10140, 2018, Pages 2607-2618

  Ambery, Philip ^a   Parker, Victoria E ^a   Stumvoll, Michael ^b   Posch, Maximilian G ^c   Heise, Tim ^d   Plum Moerschel, Leona ^e   Tsai, Lan Feng ^f   Robertson, Darren ^a   Jain, Meena ^a   Petrone, Marcella ^a   Rondinone, Cristina ^f   Hirshberg, Boaz ^f   Jermutus, Lutz ^a  

^a MEDIMMUNE LTD   (United Kingdom)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Profil   (Germany)

^e Profil Mainz   (Germany)

^f MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; MED I0382; MEDI 0382; PLACEBO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; MEDI0382; PEPTIDE;

ABDOMINAL DISTENSION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD EXAMINATION; BODY MASS; BODY WEIGHT; BODY WEIGHT LOSS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERUCTATION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEADACHE; HEALTH CARE PERSONNEL; HEART DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MAXIMUM CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OBESITY; PEPTIDES; WEIGHT LOSS;

EID: 85048885004     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30726-8     Document Type: Article

References (61)

1. American Diabetes Association, Standards of medical care in diabetes—2017. Diabetes Care 40:suppl 1 (2017), S1–S129.
2. UKPDS Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
3. UKPDS Group, UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 39 (1990), 905–912.
4. Mann, DM, Woodward, M, Muntner, P, Preventing diabetes complications: are we too glucocentric?. Int J Clin Pract 64 (2010), 1024–1027.
5. Knowler, WC, Barrett-Connor, E, Fowler, SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
6. Kempf, K, Altpeter, B, Berger, J, et al. Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: a randomized controlled trial. Diabetes Care 40 (2017), 863–871.
7. Franz, MJ, Boucher, JL, Rutten-Ramos, S, VanWormer, JJ, Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 115 (2015), 1447–1463.
8. Goldstein, DJ, Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16 (1992), 397–415.
9. Grams, J, Garvey, WT, Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action. Curr Obes Rep 4 (2015), 287–302.
10. Taylor, R, Type 2 diabetes: etiology and reversibility. Diabetes Care 36 (2013), 1047–1055.
11. Larger, E, Weight gain and insulin treatment. Diabetes Metab, 31, 2005, 4S51 4S56.
12. Piya, MK, Tahrani, AA, Barnett, AH, Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol 70 (2010), 631–644.
13. Potts, JE, Gray, LJ, Brady, EM, Khunti, K, Davies, MJ, Bodicoat, DH, The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One, 10, 2015, e0126769.
14. Mingrone, G, Panunzi, S, De Gaetano, A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366 (2012), 1577–1585.
15. Schauer, PR, Bhatt, DL, Kirwan, JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med 376 (2017), 641–651.
16. Sjöström, L, Lindroos, AK, Peltonen, M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004), 2683–2693.
17. 2. Surg Obes Relat Dis 12 (2016), 1357–1363.
18. Keidar, A, Bariatric surgery for type 2 diabetes reversal: the risks. Diabetes Care 34:suppl 2 (2011), S361–S366.
19. Buchwald, H, Avidor, Y, Braunwald, E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004), 1724–1737.
20. Lean, MEJ, Leslie, WS, Barnes, AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391 (2018), 541–551.
21. Wewer Albrechtsen, NJ, Hornburg, D, Albrechtsen, R, et al. Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma. EBioMedicine 7 (2016), 112–120.
22. Ionut, V, Burch, M, Youdim, A, Bergman, RN, Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring) 21 (2013), 1093–1103.
23. Drucker, DJ, Habener, JF, Holst, JJ, Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 127 (2017), 4217–4227.
24. Wynne, K, Park, AJ, Small, CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30 (2006), 1729–1736.
25. Choudhury, SM, Tan, TM, Bloom, SR, Gastrointestinal hormones and their role in obesity. Curr Opin Endocrinol Diabetes Obes 23 (2016), 18–22.
26. Khajavi, N, Biebermann, H, Tschöp, M, DiMarchi, R, Treatment of diabetes and obesity by rationally designed peptide agonists functioning at multiple metabolic receptors. Endocr Dev 32 (2017), 165–182.
27. Day, JW, Ottaway, N, Patterson, JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5 (2009), 749–757.
28. Henderson, SJ, Konkar, A, Hornigold, DC, et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18 (2016), 1176–1190.
29. Ambery, P, Klammt, S, Petrone, M, et al. MEDI0382, a GLP-1-glucagon dual agonist, meets safety and tolerability endpoints in a single-dose study in healthy volunteers. Diabetes, 65(suppl 1A), 2016, LB29 107-LB (abstr).
30. Meier, JJ, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
31. Kapitza, C, Dahl, K, Jacobsen, JB, Axelsen, MB, Flint, A, Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia 60 (2017), 1390–1399.
32. Riddle, MC, Basal glucose can be controlled, but the prandial problem persists—it's the next target!. Diabetes Care 40 (2017), 291–300.
33. Farr, OM, Tsoukas, MA, Triantafyllou, G, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism 65 (2016), 945–953.
34. Jacobsen, SH, Olesen, SC, Dirksen, C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 22 (2012), 1084–1096.
35. Jørgensen, NB, Jacobsen, SH, Dirksen, C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 303 (2012), E122–E131.
36. McClean, PL, Irwin, N, Cassidy, RS, Holst, JJ, Gault, VA, Flatt, PR, GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293 (2007), E1746–E1755.
37. Vilsbøll, T, Zdravkovic, M, Le-Thi, T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007), 1608–1610.
38. Buse, JB, Nauck, M, Forst, T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
39. Buse, JB, Rosenstock, J, Sesti, G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009), 39–47.
40. Buse, JB, Vilsbøll, T, Thurman, J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37 (2014), 2926–2933.
41. Ahrén, B, Leguizamo Dimas, A, Miossec, P, Saubadu, S, Aronson, R, Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36 (2013), 2543–2550.
42. Rosenstock, J, Reusch, J, Bush, M, Yang, F, Stewart, M, Albiglutide Study Group, Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32 (2009), 1880–1886.
43. Home, PD, Shamanna, P, Stewart, M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab 17 (2015), 179–187.
44. Nauck, MA, Petrie, JR, Sesti, G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39 (2016), 231–241.
45. Umpierrez, G, Tofé Povedano, S, Perez Manghi, F, Shurzinske, L, Pechtner, V, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37 (2014), 2168–2176.
46. Davies, MJ, Bergenstal, R, Bode, B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
47. Heath, ML, Kow, L, Slavotinek, JP, Valentine, R, Toouli, J, Thompson, CH, Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery. Metabolism 58 (2009), 753–758.
48. Fox, CS, Massaro, JM, Hoffmann, U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116 (2007), 39–48.
49. Abraham, TM, Pedley, A, Massaro, JM, Hoffmann, U, Fox, CS, Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation 132 (2015), 1639–1647.
50. Rosenquist, KJ, Pedley, A, Massaro, JM, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. JACC Cardiovasc Imaging 6 (2013), 762–771.
51. Petit, JM, Cercueil, JP, Loffroy, R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD Study. J Clin Endocrinol Metab 102 (2017), 407–415.
52. Patel, NS, Doycheva, I, Peterson, MR, et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 13, 2015, 561 68.e1.
53. Keller, U, Shulman, G, Effect of glucagon on hepatic fatty acid oxidation and ketogenesis in conscious dogs. Am J Physiol 237 (1979), E121–E129.
54. Guzman, CB, Zhang, XM, Liu, R, et al. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes Metab 19 (2017), 1521–1528.
55. Cusi, K, Sanyal, AJ, Zhang, S, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab 19 (2017), 1630–1634.
56. Prasad-Reddy, L, Isaacs, D, A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context, 4, 2015, 212283.
57. Gough, SC, Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab 14:suppl 2 (2012), 33–40.
58. Agersø, H, Jensen, LB, Elbrønd, B, Rolan, P, Zdravkovic, M, The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 (2002), 195–202.
59. Rayner, CK, Jones, KL, Wu, T, Horowitz, M, Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders. Diabetes Obes Metab 19 (2017), 309–312.
60. Kumarathurai, P, Anholm, C, Fabricius-Bjerre, A, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. J Hypertens 35 (2017), 1070–1078.
61. Meier, JJ, Rosenstock, J, Hincelin-Méry, A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 38 (2015), 1263–1273.